Whole-body diffusion-weighted imaging: The added value to whole-body MRI at initial diagnosis of lymphoma

American Journal of Roentgenology

Volumn 197, Issue 3, 2011, Pages

  Gu, Jing ^a   Chan, Tao ^a   Zhang, Jingbo ^a   Leung, Anskar Y H ^a   Kwong, Yok Lam ^a   Khong, Pek Lan ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Diffusion weighted imaging; DWI; FDG avid lymphoma; PET CT; Whole body MRI

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ABDOMEN; ADULT; AGED; ARTICLE; BONE MARROW; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGING SYSTEM; INTERMETHOD COMPARISON; KIDNEY; LABORATORY DIAGNOSIS; LYMPHOMA; MALE; PARAAORTIC LYMPH NODE; PELVIS LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REFERENCE VALUE; SENSITIVITY ANALYSIS; WHOLE BODY MRI;

ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 80052213872     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.10.5692     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66
2. Hong Kong Cancer Registry, Hospital Authority of Hong Kong. Hong Kong cancer statistics 2005. www3.ha.org.hk/cancereg/eng/annual/a.asp. Accessed October 10, 2007
3. Schoder H, Noy A, Gonen M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:4643-4651 (Pubitemid 46224066)
4. Juweid ME, Cheson BD. Role of positron emission tomography in lymphoma. J Clin Oncol 2005; 23:4577-4580 (Pubitemid 46224057)
5. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25:571-578 (Pubitemid 350002965)
6. la Fougere C, Hundt W, Brockel N, et al. Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2006; 33:1417-1425 (Pubitemid 44885407)
7. Lauenstein TC, Goehde SC, Herborn CU, et al. Whole-body MR imaging: evaluation of patients for metastases. Radiology 2004; 233:139-148 (Pubitemid 39280968)
8. Brenner DJ, Elliston CD. Estimated radiation risks potentially associated with full-body CT screening. Radiology 2004; 232:735-738 (Pubitemid 39100257)
9. Kellenberger CJ, Miller SF, Khan M, Gilday DL, Weitzman S, Babyn PS. Initial experience with FSE STIR whole-body MR imaging for staging lymphoma in children. Eur Radiol 2004; 14:1829-1841 (Pubitemid 39386632)
10. Brennan DD, Gleeson T, Coate LE, Cronin C, Carney D, Eustace SJ. A comparison of whole-body MRI and CT for the staging of lymphoma. AJR 2005; 185:711-716
11. Kwee TC, Kwee RM, Verdonck LF, Bierings MB, Nievelstein RA. Magnetic resonance imaging for the detection of bone marrow involvement in malignant lymphoma. Br J Haematol 2008; 141:60-68 (Pubitemid 351350610)
12. Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van Cauteren M. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 2004; 22:275-282 (Pubitemid 39264807)
13. Hayashida Y, Hirai T, Morishita S, et al. Diffusion- weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity. AJNR 2006; 27:1419-1425 (Pubitemid 44260120)
14. Gu J, Khong PL, Wang S, Chan Q, Law W, Zhang J. Quantitative assessment of diffusion-weighted MR imaging in patients with primary rectal cancer: correlation with FDG-PET/CT. Mol Imaging Biol 2010 Sep 25 [Epub ahead of print]
15. Kanauchi N, Oizumi H, Honma T, et al. Role of diffusion-weighted magnetic resonance imaging for predicting of tumor invasiveness for clinical stage IA non-small cell lung cancer. Eur J Cardiothorac Surg 2009; 35:706-710; discussion, 710-711
16. Taouli B, Thakur RK, Mannelli L, et al. Renal lesions: characterization with diffusion-weighted imaging versus contrast-enhanced MR imaging. Radiology 2009; 251:398-407
17. Dudeck O, Zeile M, Pink D, et al. Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas. J Magn Reson Imaging 2008; 27: 1109-1113 (Pubitemid 351614624)
18. Murtz P, Krautmacher C, Traber F, Gieseke J, Schild HH, Willinek WA. Diffusion-weighted whole-body MR imaging with background body signal suppression: a feasibility study at 3.0 Tesla. Eur Radiol 2007; 17:3031-3037 (Pubitemid 350142327)
19. Kwee TC, Kwee RM, Nievelstein RA. Imaging in staging of malignant lymphoma: a systematic review. Blood 2008; 111:504-516
20. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR 2007; 188:1622-1635 (Pubitemid 46866868)
21. Kwee TC, van Ufford HM, Beek FJ, et al. Whole-body MRI, including diffusion-weighted imaging, for the initial staging of malignant lymphoma: comparison to computed tomography. Invest Radiol 2009; 44:683-690
22. Lin C, Luciani A, Itti E, et al. Whole-body diffusion- weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma. Eur Radiol 2010; 20:2027-2038
23. Weiler-Sagie M, Bushelev O, Epelbaum R, et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 2010; 51:25-30
24. Chan WK, Au WY, Wong CY, et al. Metabolic activity measured by F-18 FDG PET in natural killer-cell lymphoma compared to aggressive Band T-cell lymphomas. Clin Nucl Med 2010; 35:571-575
25. de Jong PA, van Ufford HM, Baarslag HJ, et al. CT and 18F-FDG PET for noninvasive detection of splenic involvement in patients with malignant lymphoma. AJR 2009; 192:745-753
26. Tsushima Y, Takano A, Taketomi-Takahashi A, Endo K. Body diffusion-weighted MR imaging using high b-value for malignant tumor screening: usefulness and necessity of referring to T2- weighted images and creating fusion images. Acad Radiol 2007; 14:643-650 (Pubitemid 46898198)
27. Delfaut EM, Beltran J, Johnson G, Rousseau J, Marchandise X, Cotten A. Fat suppression in MR imaging: techniques and pitfalls. RadioGraphics 1999; 19:373-382
28. Lauenstein TC, Goehde SC, Herborn CU, et al. Three-dimensional volumetric interpolated breathhold MR imaging for whole-body tumor staging in less than 15 minutes: a feasibility study. AJR 2002; 179:445-449 (Pubitemid 34785650)
29. Lauenstein TC, Semelka RC. Emerging techniques: whole-body screening and staging with MRI. J Magn Reson Imaging 2006; 24:489-498 (Pubitemid 44320550)
30. Lauenstein TC, Sharma P, Hughes T, et al. Evaluation of optimized inversion-recovery fat-suppression techniques for T2-weighted abdominal MR imaging. J Magn Reson Imaging 2008; 27: 1448-1454 (Pubitemid 351770702)
31. Huang B, Law MW, Khong PL. Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. Radiology 2009; 251:166-174
32. Plathow C, Walz M, Lichy MP, et al. Cost considerations for whole-body MRI and PET/CT as part of oncologic staging [in German]. Radiologe 2008; 48:384-396 (Pubitemid 351720456)
33. Kwee TC, Takahara T, Koh DM, Nievelstein RA, Luijten PR. Comparison and reproducibility of ADC measurements in breathhold, respiratory triggered, and free-breathing diffusion-weighted MR imaging of the liver. J Magn Reson Imaging 2008; 28:1141-1148